Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ACT008
MIFTS: 55

Actinic Keratosis

Categories: Cancer diseases, Genetic diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Actinic Keratosis

About this section

MalaCards integrated aliases for Actinic Keratosis:

Name: Actinic Keratosis 12 77 56 15 17 74
Senile Hyperkeratosis 12
Seborrheic Keratosis 74
Sk - Solar Keratosis 12
Actinic Keratosis 12
Keratosis, Actinic 45
Solar Keratosis 12

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:8866
ICD9CM 36 702.0
MeSH 45 D055623
NCIt 51 C3148
SNOMED-CT 69 46795000 856006
ICD10 34 L57.0
Sources

Summaries for Actinic Keratosis

About this section
MalaCards based summary : Actinic Keratosis, also known as senile hyperkeratosis, is related to squamous cell carcinoma and bowen's disease. An important gene associated with Actinic Keratosis is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Mitotic G1-G1/S phases and MicroRNAs in cancer. The drugs Aminolevulinic acid and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and kidney, and related phenotypes are growth/size/body region and behavior/neurological

Wikipedia : 77 Actinic keratosis (AK) is a pre-cancerous area of thick, scaly, or crusty skin. These growths are more... more...

Sources

Related Diseases for Actinic Keratosis

About this section

Diseases in the Actinic Keratosis family:

Keratosis, Familial Actinic

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.4 CDKN2A MMP2 PTGS2 TP53 TP63
2 bowen's disease 31.2 KRT17 PCNA
3 basal cell carcinoma 30.9 KRT17 KRT20 MC1R TP53
4 in situ carcinoma 30.8 CDKN2A KRT17 TP53
5 keratoacanthoma 30.3 FLG KRT17 TP53
6 papilloma 29.5 CDKN2A FLG KRT20 PCNA TP53 TP63
7 keratosis 11.9
8 actinic cheilitis 11.4
9 basal cell carcinoma 1 10.7
10 skin carcinoma 10.6
11 melanoma 10.5
12 vulvar intraepithelial neoplasia 10.4 MMP2 TP53
13 bladder squamous cell carcinoma 10.4 CDKN2A TP53
14 protoplasmic astrocytoma 10.4 PTGS2 TP53
15 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
16 spitz nevus 10.4 CDKN2A TP53
17 recurrent respiratory papillomatosis 10.4 PTGS2 TP53
18 multicentric osteolysis, nodulosis, and arthropathy 10.4 MMP14 MMP2
19 winchester syndrome 10.4 MMP14 MMP2
20 bizarre leiomyoma 10.4 CDKN2A PCNA
21 bladder carcinoma in situ 10.4 CDKN2A TP53
22 scrotal carcinoma 10.4 CDKN2A TP53
23 colloid adenoma 10.4 KRT20 TP53
24 thyroid lymphoma 10.4 CDKN2A TP53
25 arteriovenous fistula 10.4 MMP2 PCNA
26 vulvar disease 10.4 CDKN2A TP53
27 fibroepithelial basal cell carcinoma 10.4 KRT20 TP53
28 nasal cavity adenocarcinoma 10.3 CDKN2A TP53
29 bladder papillary transitional cell neoplasm 10.3 KRT20 TP53
30 ameloblastic carcinoma 10.3 CDKN2A TP63
31 urinary tract papillary transitional cell benign neoplasm 10.3 KRT20 TP53
32 bartholin's gland disease 10.3 CDKN2A TP53
33 tongue disease 10.3 CDKN2A MMP2 TP53
34 laryngeal disease 10.3 CDKN2A MMP2 TP53
35 cystic basal cell carcinoma 10.3 KRT20 TP63
36 supratentorial cancer 10.3 CDKN2A MMP2 TP53
37 cerebrum cancer 10.3 CDKN2A MMP2 TP53
38 vulval paget's disease 10.3 CDKN2A KRT20
39 barrett's adenocarcinoma 10.3 CDKN2A PTGS2 TP53
40 juvenile pilocytic astrocytoma 10.3 CDKN2A TNC TP53
41 esophageal disease 10.3 CDKN2A PTGS2 TP53
42 tongue cancer 10.3 CDKN2A MMP2 TP53
43 bile duct adenoma 10.3 CDKN2A KRT20
44 female reproductive system disease 10.3 CDKN2A MMP2 TP53
45 respiratory system cancer 10.3 CDKN2A MMP2 TP53
46 tongue squamous cell carcinoma 10.3 CDKN2A MMP2 TP53
47 suppressor of tumorigenicity 3 10.3 CDKN2A PCNA TP53
48 lentigo maligna melanoma 10.3 MC1R MMP2
49 endocrine gland cancer 10.3 CDKN2A MMP2 TP53
50 balanitis xerotica obliterans 10.3 CDKN2A PTGS2

Graphical network of the top 20 diseases related to Actinic Keratosis:



Diseases related to Actinic Keratosis
Sources

Symptoms & Phenotypes for Actinic Keratosis

About this section

MGI Mouse Phenotypes related to Actinic Keratosis:

47 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.33 CDKN2A KRT17 LUM MC1R MCM2 MMP14
2 behavior/neurological MP:0005386 10.3 CDKN2A LUM MC1R MCM2 MMP14 PTGS2
3 cellular MP:0005384 10.29 CDKN2A KRT17 LUM MC1R MCM2 MMP14
4 immune system MP:0005387 10.26 CDKN2A LUM MC1R MCM2 MMP14 MMP2
5 mortality/aging MP:0010768 10.22 CDKN2A KRT17 LUM MCM2 MMP14 MMP2
6 integument MP:0010771 10.21 CDKN2A KRT17 LUM MC1R MCM2 MMP14
7 cardiovascular system MP:0005385 10.2 CDKN2A LUM MMP14 MMP2 PTGS2 TP53
8 hematopoietic system MP:0005397 10.19 CDKN2A LUM MC1R MCM2 MMP14 MMP2
9 digestive/alimentary MP:0005381 10.18 CDKN2A KRT17 LUM MCM2 MMP14 PTGS2
10 endocrine/exocrine gland MP:0005379 10.16 CDKN2A MCM2 MMP14 PCNA PTGS2 TP53
11 craniofacial MP:0005382 10.13 KRT17 MC1R MMP14 MMP2 TP53 TP63
12 embryo MP:0005380 10.11 CDKN2A MCM2 MMP14 PTGS2 TP53 TP63
13 no phenotypic analysis MP:0003012 10.1 CDKN2A KRT17 MC1R MMP14 PCNA PTGS2
14 muscle MP:0005369 10.06 CDKN2A LUM MCM2 MMP14 MMP2 PTGS2
15 neoplasm MP:0002006 10.03 CDKN2A MC1R MCM2 MMP2 PTGS2 TP53
16 limbs/digits/tail MP:0005371 9.97 LUM MC1R MMP14 TP53 TP63 TYR
17 normal MP:0002873 9.97 MCM2 MMP14 MMP2 PTGS2 TNC TP53
18 reproductive system MP:0005389 9.86 CDKN2A LUM MMP14 PCNA PTGS2 TP53
19 pigmentation MP:0001186 9.8 CDKN2A KRT17 MC1R MCM2 TP53 TYR
20 respiratory system MP:0005388 9.7 CDKN2A MCM2 MMP14 MMP2 PTGS2 TP53
21 skeleton MP:0005390 9.56 CDKN2A LUM MMP14 MMP2 PTGS2 TP53
22 vision/eye MP:0005391 9.23 CDKN2A LUM MMP14 MMP2 PTGS2 TP53
Sources

Drugs & Therapeutics for Actinic Keratosis

About this section

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 51-21-8 3385
4
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
5
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 15307-86-5 3033
6
Prilocaine Approved Phase 4,Phase 1 721-50-6 4906
7
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 137-58-6 3676
8
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
9
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
10
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
11
Hydrogen peroxide Approved, Vet_approved Phase 4,Phase 2 7722-84-1 784
12
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
13
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
14
Petrolatum Approved, Investigational Phase 4,Phase 2,Early Phase 1,Not Applicable 8009-03-8
15
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 69-72-7 338
16
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
17
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492 6473866
18
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
19
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177 70789204
20
Menthol Approved Phase 4 2216-51-5 16666
21
Azathioprine Approved Phase 4 446-86-6 2265
22
Mycophenolic acid Approved Phase 4 24280-93-1 446541
23
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
24
Calcium Approved, Nutraceutical Phase 4,Phase 1,Early Phase 1,Not Applicable 7440-70-2 271
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
26
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
27
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
28
Protoporphyrin IX Experimental Phase 4,Phase 1 553-12-8
29 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Sunscreening Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Radiation-Protective Agents Phase 4,Phase 2
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Anti-Infective Agents, Local Phase 4,Phase 2,Not Applicable
42 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1,Not Applicable
45 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Vitamins Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
49 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
50 Keratolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 369)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
3 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
4 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
5 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
6 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
7 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
8 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
9 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
10 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
11 Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
12 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
13 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
14 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
15 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4 Ingenol Mebutate
16 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
17 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
18 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
19 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
20 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
21 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
22 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
23 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
24 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
25 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
26 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
27 An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses Completed NCT03487588 Phase 4 A-101 Topical Solution
28 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
29 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
30 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
31 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
32 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention Recruiting NCT03642535 Phase 4 ALA
33 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Recruiting NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
34 Treatment of Photodamaged Skin of the décolleté Recruiting NCT03573076 Phase 4
35 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Active, not recruiting NCT02990221 Phase 4 Ingenol mebutate
36 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
37 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
38 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
39 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
40 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
41 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
42 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
43 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
44 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
45 Actinic Keratoses Treatment With Metvix® in Combination With Light Unknown status NCT02373371 Phase 3 Metvix®
46 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
47 5fluorouracil for Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
48 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
49 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00942604 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
50 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00742391 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Sources

Genetic Tests for Actinic Keratosis

About this section
Sources

Anatomical Context for Actinic Keratosis

About this section

MalaCards organs/tissues related to Actinic Keratosis:

42
Skin, Testes, Kidney, T Cells, Liver, Bone, Neutrophil
Sources

Publications for Actinic Keratosis

About this section

Articles related to Actinic Keratosis:

(show top 50) (show all 882)
# Title Authors Year
1
Actinic keratosis and imiquimod: a review of novel carriers and patents. ( 30582385 )
2019
2
'Surprisingly little evidence' on how best to treat actinic keratosis in organ transplant recipients. ( 30604541 )
2019
3
Occurrence of newly discovered human polyomaviruses in skin of liver transplant recipients and their relation with squamous cell carcinoma in situ and actinic keratosis - a single-center cohort study. ( 30632206 )
2019
4
Methyl aminolevulinate daylight photodynamic therapy applied at home for non-hyperkeratotic actinic keratosis of the face or scalp: an open, interventional study conducted in Germany. ( 30633376 )
2019
5
Healthcare utilization and management of actinic keratosis in primary and secondary care: a complementary database analysis. ( 30636037 )
2019
6
Relative efficacy of 5-fluorouracil compared with other treatments among patients with actinic keratosis: A network meta-analysis. ( 30638294 )
2019
7
Non-invasive monitoring of subclinical and clinical actinic keratosis of face and scalp under topical treatment with ingenolmebutate gel 150 mcg/gby means of reflectance confocal microscopy and optical coherence tomography: new perspectives and comparison of diagnostic techniques. ( 30653833 )
2019
8
Photoaging and actinic keratosis in Danish outdoor and indoor workers. ( 30687943 )
2019
9
A Comparison of the Efficacy of Ablative Fractional Laser Assisted Photodynamic Therapy according to Ablative Depth for Actinic Keratosis: A Single-blinded, Randomized, Comparative, Prospective Study. ( 30690046 )
2019
10
Fluorescent photodiagnostic evaluation of field cancerization treated with a medical device containing piroxicam 0.8% and sunscreen SPF 50+ for actinic keratosis. ( 30690758 )
2019
11
Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. ( 30710390 )
2019
12
Resiquimod for actinic keratosis: is this a new treatment option? ( 30714105 )
2019
13
REPLY to 'Comment on "Anti-aging effects of ingenol mebutate for patients with actinic keratosis" and phenol-croton oil peelings'. ( 30716403 )
2019
14
About "Anti-aging effects of ingenol mebutate for patients with actinic keratosis" and phenol-croton oil peelings. ( 30716406 )
2019
15
Daylight photodynamic therapy in 25 patients with actinic keratosis and evaluation of efficacy by confocal microscopy. ( 30721758 )
2019
16
Iceberg sign as a dermoscopic clue of actinic keratosis neglecta. ( 30742717 )
2019
17
Bundled payment for actinic keratosis management: Pilot evaluation of developed models. ( 30744876 )
2019
18
Photodynamic therapy for actinic keratosis of the forehead and scalp with the Aktilite CL 128: is there a cut-off value for PpIX-weighted irradiance for effective treatment? ( 30762242 )
2019
19
Late fusion of deep and shallow features to improve discrimination of actinic keratosis from normal skin using clinical photography. ( 30762255 )
2019
20
Conceptual, Statistical and Clinical interpretation of results from A Systematic Review and Meta-Analysis of Cryosurgery combined with Topical interventions for Actinic Keratosis. ( 30767194 )
2019
21
Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece. ( 30779341 )
2019
22
Insight into the management of actinic keratosis: a qualitative interview study among general practitioners and dermatologists. ( 30801664 )
2019
23
Monitoring sequential treatment of actinic keratosis using post-processed images: ingenol mebutate and cryosurgery. ( 30815968 )
2019
24
Reducing Unpleasant Side Effects of Topical 5-Flourouracil Treatment for Actinic Keratosis: A Randomized Controlled Trial. ( 30821548 )
2019
25
Comprehensive analysis of β and γ Human Papillomaviruses in actinic keratosis and apparently healthy skin of elderly patients. ( 30825192 )
2019
26
Daylight photodynamic therapy for severe facial and scalp actinic keratosis: a prospective non-sponsored single-centre study employing the actinic keratosis area and severity index (AKASI). ( 30827943 )
2019
27
Efficacy of topical Imiquimod 3.75% in the treatment of Actinic Keratosis of the scalp in immunosuppressed patients: our case series. ( 30836026 )
2019
28
What is the most relevent factor during ALA-PDT？ A multi-center, open clinical pain score research about actinic keratosis, acne and condylomatata acuminata. ( 30836211 )
2019
29
A randomized, double-blind trial comparing 5-aminolevulinic acid nanoemulsion (BF-200 ALA) with methyl-5-aminolevulinate (MAL) in daylight photodynamic therapy for actinic keratosis. ( 30845350 )
2019
30
Randomized Trial of Four Treatment Approaches for Actinic Keratosis. ( 30855743 )
2019
31
Split face study comparing conventional mal photodynamic therapy in multiple actinic keratosis with complete time versus half-time red light led conventional illumination. ( 30868672 )
2019
32
Geographic variability of pricing and insurance coverage of topical actinic keratosis therapy - a survey-based study. ( 30910661 )
2019
33
Actinic keratosis and diabetes complications: A nationwide population-based study in South Korea (2009-2015). ( 29249611 )
2019
34
Efficacy Endpoints in Clinical Trials in Actinic Keratosis. ( 29916197 )
2018
35
Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. ( 29779986 )
2018
36
A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis. ( 29620004 )
2018
37
Comparison of 10 efficient protocols for photodynamic therapy of actinic keratosis: How relevant are effective light dose and local damage in predicting the complete response rate at 3 months? ( 29667728 )
2018
38
Reflectance confocal microscopy: a crucial role for actinic keratosis treatment monitoring. ( 29846971 )
2018
39
Successful Treatment of Actinic Keratosis with Kanuka Honey. ( 29955399 )
2018
40
A multi-centre, open, investigator initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0.015% on the face and scalp, and 0.05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT). ( 29355904 )
2018
41
Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. ( 29920789 )
2018
42
MART-1-Labeled Melanocyte Density and Distribution in Actinic Keratosis and Squamous Cell Cancer in situ: Pagetoid Melanocytes are a Potential Source of Misdiagnosis as Melanoma in Situ. ( 29943494 )
2018
43
Differential proteomic analysis of actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma by label-free LC-MS/MS. ( 29665991 )
2018
44
Treatment of Grade II and III Actinic Keratosis Lesions with a Film-Forming Medical Device Containing Sunscreen/Piroxicam 0.8% and a Retinoic Acid/Glycolic Gel: A Pilot Trial. ( 29855896 )
2018
45
Topical formulations of delta-aminolevulinic acid for the treatment of actinic keratosis: Characterization and efficacy evaluation. ( 29407554 )
2018
46
Photodynamic therapy with the use of superluminescent diodes (sLED) in the treatment of actinic keratosis. ( 29684690 )
2018
47
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up. ( 29441544 )
2018
48
Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment. ( 29351725 )
2018
49
Energy-based devices for actinic keratosis field therapy. ( 29894524 )
2018
50
Teledermatology-driven topical therapy of actinic keratosis: a comparative study of clinical effectiveness and compliance. ( 29797670 )
2018
Sources

Variations for Actinic Keratosis

About this section
Sources

Expression for Actinic Keratosis

About this section
Search GEO for disease gene expression data for Actinic Keratosis.
Sources

Pathways for Actinic Keratosis

About this section

Pathways related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Mitotic G1-G1/S phases 67
Show member pathways
 12.31 CDKN2A MCM2 PCNA TP53
2
MicroRNAs in cancer 38
12.13 CDKN2A PTGS2 TNC TP53 TP63
3
Cell cycle 38 1
12.09 CDKN2A MCM2 PCNA TP53
4
DNA Damage 4
12.02 CDKN2A MCM2 PCNA TP53 TP63
5
Colorectal Cancer Metastasis 65
11.89 MMP14 MMP2 PTGS2 TP53
6
Interleukin-4 and 13 signaling 67
11.74 MMP2 PTGS2 TP53
7
Direct p53 effectors 1
11.74 MMP2 PCNA TP53 TP63
8
Angiogenesis (CST) 4
11.6 MMP2 PTGS2 TNC
9
Bladder cancer 38 1
11.5 CDKN2A MMP2 TP53
10
Photodynamic therapy-induced AP-1 survival signaling. 1
11.29 CDKN2A MMP2 TP53
11
Senescence and Autophagy in Cancer 1
11.28 CDKN2A MMP14 PCNA TP53
12
Inhibition of Ribosome Biogenesis by p14(ARF) 65
10.87 CDKN2A TP53
13
TP53 Network 1
Show member pathways
 10.14 CDKN2A TP53 TP63
Sources

GO Terms for Actinic Keratosis

About this section

Cellular components related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.26 LUM MMP14 MMP2 TNC
2 collagen-containing extracellular matrix GO:0062023 8.92 FLG LUM MMP2 TNC

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.8 PCNA TP53 TP63 TYR
2 apoptotic process GO:0006915 9.72 CDKN2A KRT20 MCM2 TP53 TP63
3 response to organic cyclic compound GO:0014070 9.61 LUM MMP14 PTGS2
4 response to oxidative stress GO:0006979 9.58 MMP14 PCNA PTGS2
5 establishment of skin barrier GO:0061436 9.48 FLG TP63
6 response to vitamin D GO:0033280 9.46 PTGS2 TYR
7 cornification GO:0070268 9.43 FLG KRT17 KRT20
8 intermediate filament organization GO:0045109 9.37 KRT17 KRT20
9 melanin biosynthetic process GO:0042438 9.16 MC1R TYR
10 replicative senescence GO:0090399 8.96 CDKN2A TP53
11 cellular response to UV GO:0034644 8.8 PCNA PTGS2 TP53

Molecular functions related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.53 CDKN2A FLG KRT17 KRT20 LUM MC1R
2 enzyme binding GO:0019899 9.26 MCM2 PCNA PTGS2 TP53
Sources

Sources for Actinic Keratosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....